Based on the idea that cGAS-STING activation can induce a potent immune-mediated response against tumor cells, several studies have sought to explore the possibility of using STING agonists as adjuvants or chemotherapeutic agents to enhance immunotherapy. The gene discussed is CGAS; the disease is neoplasm.